Antiphospholipid syndrome (aps) in children

ME Pombo, R Merino, D Pascual, MV Cuesta, A Aguado, J García-ConsuegraRheumatology Service Pediatric Rheumatology Unit Inmunology Service Hematology Service Internal Medicine Service, Hospital Universitario La Paz, Madrid, SpainBackground Objectives To evaluate clinical features and management options of persistent antiphospholipid antibodies (aPL) in children. Methods Retrospective chart review of patients, seen between 1987 and 2000. Results Six patients with ages at diagnosis ranging from 9 to 13 years are presented. One of them with primary APS and 3 with SLE and asymptomatic aPL. The clinical manifestations are shown in the Table 1 . All of the patients included were positive for lupus anticoagulant and all of them except the case 4 had positive tests for aCL and Aβ 2GPI . Abstract AB0102 Table 1 Clinical manifestations and treatment Thrombotic events Prophylactic treatment Outcome Follow up (years) Recurrences Case 1 DVT+Pulmonary embolism Warfarin Resolved 7 No Case 2 Transient ischaemic brain attack Aspirin Resolved 9 No Case 3 DVT Aspirin Resolved 9 No Case 4 - Aspirin Unchanged 9 - Case 5 - Aspirin Unchanged 8 - Case 6 - Aspirin Unchanged 8 - Conclusion In paediatric patients with aPL, the risk of thrombosis, their recurrences and the management of oral anticoagulation may be different from adults. Citation: Ann Rheum Dis, volume 60, supplement 1, year 2001, page A95Session: Anti-phospholipid syndrome